Compare TW & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TW | ROIV |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 23.2B |
| IPO Year | 2019 | 2021 |
| Metric | TW | ROIV |
|---|---|---|
| Price | $102.24 | $34.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $135.25 | $28.94 |
| AVG Volume (30 Days) | 1.4M | ★ 4.6M |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $892,659,000.00 | $8,260,000.00 |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $10.66 | $744.61 |
| P/E Ratio | $103.99 | ★ N/A |
| Revenue Growth | ★ 15.10 | N/A |
| 52 Week Low | $91.42 | $10.90 |
| 52 Week High | $147.49 | $37.00 |
| Indicator | TW | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 55.66 |
| Support Level | $96.84 | $33.56 |
| Resistance Level | $103.45 | $37.00 |
| Average True Range (ATR) | 2.75 | 1.08 |
| MACD | 0.39 | -0.24 |
| Stochastic Oscillator | 93.85 | 34.04 |
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.